Key facts
- Umami Bioworks’s last known valuation is $63.6M (Sep 2024).
- It has raised $34.1M; the latest was Later Stage VC in Feb 2026.
- Notable investors include Plug and Play Tech Center, Y Combinator, Creative Destruction Lab, MassChallenge, Entrepreneurs First — 42 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 42 names
- ·Watchlist + deal alerts for Umami Bioworks
- ·The full record, as it builds
Funding rounds
No funding rounds for Umami Bioworks are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Umami Bioworks
Producer of cell-based food products intended to offer a healthy alternative to seafood. The company's products are directly made from fish cells and tissue and are free from mercury, antibiotics, microplastics, and ocean pollutants, enabling customers to find affordable, cell-cultured seafood and meat with low-cost, serum-free media and novel marine cell lines.
- Sector
- Consumer Products and Services (B2C)
- HQ
- Singapore, Singapore
- Founded
- 2020
- Employees
- 40
- Website
- umamibioworks.com/
- Ownership
- Privately Held (backing)
Umami Bioworks doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Umami Bioworks shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Umami Bioworks in its N-PORT filings yet. We sweep new filings monthly.